COVID-19 Disease

• EMA approval · 2026-08-26
  EMA Authorised: Spikevax (previously COVID-19 Vaccine Moderna) (single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2) — Moderna Biotech Spain, S.L.

  The EMA has authorised Spikevax (Moderna) for use in the EU; it is an mRNA vaccine encoding the SARS-CoV-2 spike protein for COVID-19.

• EMA approval · 2026-07-24
  EMA Authorised: Comirnaty (single-stranded, 5’-capped messenger RNA produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2) — BioNTech Manufacturing GmbH

  EMA authorises Comirnaty (BioNTech) for COVID-19 virus infection as a vaccine based on mRNA technology.

• EMA approval · 2026-07-13
  EMA Authorised: Paxlovid (nirmatrelvir;ritonavir) — Pfizer Europe MA EEIG

  EMA authorised Paxlovid (nirmatrelvir/ritonavir) for COVID-19 virus infection in Europe.

• CLINICAL_TRIALS trial_result · 2023-12-20
  Clinical Trial Update: Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure [Phase 2, Phase 3]

  Phase 2/3 clinical trial update for INO-4800 in adults at high risk for SARS-CoV-2 exposure; study terminated with results posted.

• CLINICAL_TRIALS trial_result · 2023-08-08
  Clinical Trial Update: A Study of LAM-002A for the Prevention of Progression of COVID-19 [Phase 2]

  Phase 2 trial of LAM-002A for prevention of progression of COVID-19 completed; results posted in 2023.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2021-08-16
  Clinical Trial Update: Efficacy, Immunogenicity and Safety of BBIBP-CorV Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. [Phase 3]

  Phase 3 clinical trial update evaluating efficacy, immunogenicity, and safety of BBIBP-CorV vaccine against COVID-19.

• CLINICAL_TRIALS trial_result · 2021-07-20
  Clinical Trial Update: A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 Infection [Phase 2]

  Phase II randomized study evaluating exosomes overexpressing CD24 to prevent deterioration in moderate to severe COVID-19 patients; status n…

• CLINICAL_TRIALS trial_result · 2021-05-10
  Clinical Trial Update: Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease [Phase 2]

  Phase 2 clinical trial assessing safety and efficacy of convalescent plasma in patients with severe COVID-19 disease has completed.